President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

But the study warns the drugs may also cause muscle loss, which is essential for strength, posture, and long-term health. Too much lean mass loss, researchers say, could increase the risk of heart ...

For 14 years, Jesse’s mind spiraled. So did his weight. The medications he took for schizophrenia drove his weight up until ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...